NYLIM
AURA icon

New York Life Investment Management’s Aura Biosciences AURA Stock Holding History

New York Life Investment Management’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,734
Closed -$367K – 901
2024
Q1 		$367K Buy
+46,734
New +$387K ﹤0.01% 1057

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

New York Life Investment Management's AURA Position: Q2 2024 in Review

New York Life Investment Management sold out of Aura Biosciences (AURA) in Q2 2024, closing a stake of 46,734 shares — an estimated $367K sold.

New York Life Investment Management first reported a position in AURA in Q1 2024 and held it in 1 quarter. The position peaked at $367K in Q1 2024. 75 funds tracked by Wall St. Rank hold AURA as of Q2 2024.

  • New York Life Investment Management reported no remaining Aura Biosciences position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 46,734 Aura Biosciences shares in Q2 2024, an estimated $367K.
  • New York Life Investment Management first reported a position in Aura Biosciences in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Aura Biosciences position peaked at $367K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.